中文
中文
为了病患而驱动的创新
Patient-first cell therapy innovation

T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma.
  • 0
Zhang Y., Mudgal P., Wang L., Wu H., Huang N., Alexander P.B., Gao Z., Ji N. & Li Q.-J. (2020) T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma. OncoImmunology, 9(1):1749476. (PMCID: PMC7153824)


https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153824/

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer
关于天科雅
研究与发展
产品及临床
新闻与媒体
招贤纳士

Copyright © 2019 天科雅生物医药科技有限公司

粤公网安备 44011502000528号

粤ICP备20056630号 Powered by vancheer